Detailed Information
Cited 14 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
A multicenter phase II randomized trial of durvalumab (D) versus physician's choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).
- Authors
- Tan, DSP[Tan, David Shao Peng]; Choi, CH[Choi, Chel Hun]; Ngoi, N[Ngoi, Natalie]; Sun, H[Sun, Haoyang]; Heong, V[Heong, Valerie]; Ow, SGW[Ow, Samuel Guan Wei]; Chay, WY[Chay, Wen Yee]; Kim, HS[Kim, Hee Seung]; Lim, YW[Lim, Yi Wan]; Goss, G[Goss, Geraldine]; Goh, JC[Goh, Jeffrey C.]; Luo, V[Luo, Vilianty]; Tai, BC[Tai, Bee Choo]; Lim, D[Lim, Diana]; Kaliaperumal, N[Kaliaperumal, Nivashini]; Au, VB[Au, Veonice Bijin]; Connolly, J[Connolly, John]; Kim, JW[Kim, Jae-Weon]; Friedlander, M[Friedlander, Michael]; Kim, K[Kim, Kidong]
- Issue Date
- 1-Jun-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.